Program
AZD1163
A development code.
Its studies are mostly in Arthritis, Rheumatoid, led by AstraZeneca.
Furthest: phase 2, since Dec 1, 20252 company-led studies, 1 open or runningNext primary completion: Nov 12, 2027 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AstraZeneca | 21 open or running | phase 2since Dec 1, 2025 | Oct 23, 2023 | Nov 12, 2027phase 2 · NCT07276581 |
- Named in AstraZeneca’s own pipeline as
AZD1163
, phase 2, as of Oct 30, 2026 (source).
Also a collaborator on its studies: parexel.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 23, 2023First study: phase 1 study in Arthritis, RheumatoidFirst studyNCT06103877 · 108 enrolled · United States, Germany
- Dec 1, 2025Phase 2 study in Arthritis, RheumatoidPhase 2 reachedNCT07276581 · 320 planned · United States, Argentina, Brazil and more
Ahead
- Nov 12, 2027Primary completion: phase 2 study in Arthritis, RheumatoidNCT07276581
TargetBeta
“AZD1163 is a novel bispecific antibody that inhibits the activity of extracellular peptidyl arginine deiminase 2 (PAD2) and peptidyl arginine deiminase 4 (PAD4) enzymes, which are responsible for protein citrullination.”study text, read by Claude · the study
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07276581Arthritis, Rheumatoid · United States, Argentina, Brazil and more | 2 | Recruiting | Nov 12, 2027 | 320 |
| NCT06103877Arthritis, Rheumatoid · United States, Germany | 1 | Completed | Jan 13, 2026 | 108 |
How it is read
Names in the registry
- “AZD1163”, 2 entries
Codes read as this program: AZD1163.
Conditions, from the studies’ own filings
- Arthritis, Rheumatoid, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.